ClinicalTrials.gg
CompletedNCT02504294Updated Jun 13, 2018Results posted

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

A Phase 3 interventional study of Epoetin Hospira Arm and Standard of Care Arm in Chronic Kidney Disease (CKD), sponsored by Pfizer. Completed at 45 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-13.

Sponsored by Pfizer · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic — 1 open to participants now, 1 under way, none of them phase 3. Epoetin Alfa · Renal Insufficiency, Chronic.

Enrollment
5th of 25
432 · median 157
Started
2015
with 1 other
Phase 3
10 of 25
none open now
Registered
22nd of 25
by date
Lead sponsor
3 of 25
Pfizer

Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, this one is the 5th largest by enrollment, is one of 2 that started in 2015, is one of 10 in phase 3, and was the 22nd registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

1 of the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.

Read the detailed description

Primary Objective: To evaluate switching from Epogen to Epoetin Hospira for maintenance of hemoglobin levels in anemic chronic kidney disease (CKD) subjects on hemodialysis using a specified algorithm for the dosing of erythropoietin stimulating agents (ESA).

Secondary Objective: To evaluate switching from Epogen to Epoetin Hospira on the dosing of ESA in anemic CKD subjects on hemodialysis using a specified algorithm for the dosing of ESA.

Exploratory Objectives: To generate hypotheses regarding maintenance of hemoglobin levels, dosing of ESA, intravenous (IV) iron dosing requirements, transferrin saturation (TSAT) levels and ferritin levels associated with the switch from Epogen to Epoetin Hospira in anemic CKD subjects on hemodialysis using specified algorithms for the dosing of ESA and for the dosing of IV iron, that are standard of care.

03

Conditions studied

  • Chronic Kidney Disease (CKD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible to be entered into the study will meet all of the following criteria:

  1. Adult female or male subjects; age ≥ 18 years.
  2. End stage renal disease subjects treated in-center with the modality of hemodialysis for ≥ 120 days.
  3. Diagnosed with anemia.
  4. Administered routine Epogen therapy for at least 16 weeks by an IV route for treatment of anemia using an Epogen version of an FMCNA dosing algorithm for ESA, and did not miss more than 3 prescribed doses of Epogen within 12 weeks prior to randomization.
  5. Currently using the IV Epogen version of the ESA dosing algorithm cMAB 5 (inclusive of versions 5.0, 5.1, ...) for anemia management.
  6. Receiving hemodialysis at a clinic using the FMCNA dosing algorithm for IV iron that is the FMCNA standard of care treatment for iron replacement.

Exclusion criteria

Exclusion Criteria

Subjects that meet any of the following criteria will be ineligible to be entered into the interventional cohort:

  1. Subjects unable to provide a signed and dated for this clinical research study.
  2. As determined by the Investigator, female subjects of child bearing potential who do not agree to use a highly effective method of .
  3. Any condition as determined by the investigator that would place a subject at an increased risk, or preclude subject's full compliance with the study procedures and visits.
  4. Female subjects who are known to be or found to be, pregnant or lactating.
  5. Subjects that are not a candidate for ESA therapies per the label warnings listed in the package insert for Epogen and/or to Epoetin Hospira listed in the Investigators' Brochure; or have had a known positive test for anti-rhEPO antibodies.
  6. Treatment with any drug within 30 days prior to randomization and throughout this clinical trial.
  7. Diagnosed with any concurrent condition that could lead to greater-than-normal loss of blood, including but not limited to:

    • Menorrhagia, peptic ulcer disease, gastrointestinal bleeding, blood dyscrasia, hemoglobinopathy
    • Use of anticoagulation therapy, including warfarin with a target (INR) of 2 or greater Anti- therapy (e.g. aspirin or clopidogrel) is permitted, as is heparin given during hemodialysis. Low-dose warfarin is permitted and defined as the presence of at least two INR values less than or equal to 1.5 during the 120 days prior to enrollment and no values exceeding 1.5 at any time after 120 days prior to enrollment.

    Subjects started on warfarin with a known INR goal of 2.0 or greater are to receive no further treatment with the study drugs, but follow up visits can continue.

    Subjects on warfarin who meet criteria to enter the study are terminated if an INR > 2.0 is discovered or if no INR is available for 60 days.

  8. History of transfusion of any blood product in the past 3 months, or 2 or more transfusions in the past 1 year; or donated or lost > 475 mL blood volume (including plasmapheresis) in the past 3 months.
  9. Subjects currently receiving a long acting ESA, or who have received a long acting ESA in the 16 weeks prior to study randomization
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
432 participants (actual)

Study arms

  • Other
    Epoetin Hospira

    Epoetin Hospira Arm

    Biological: Epoetin Hospira Arm · Drug: IV Iron

  • Other
    Standard of Care

    Standard of care arm

    Other: Standard of Care Arm · Drug: IV Iron

Interventions

  • Epoetin Hospira Arm: Epoetin Hospira will be administered intravenously (IV) per the analogous version of the Fresenius Medical Care North America (FMCNA) cMAB 1 (inclusive of version 1.0, 1.1,...)erythropoietin stimulating agents (ESA) dosing algorithm for Epoetin Hospira for 24 weeks. Subjects will have Epoetin Hospira initiated using the same ESA dose level and frequency of administration for Epogen prior to randomization into the trial. Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.

  • OtherStandard of Care Arm

    Standard of care arm: No interventions will be performed in this arm for the clinical study; and subjects will receive ongoing standard of care, which includes Epogen administered IV per the FMCNA cMAB 5 (inclusive of versions 5.0, 5.1,....) ESA dosing algorithm and IV iron per the FMCNA protocol that is standard of care, at FMCNA clinics during the contemporaneous 24 week period.

  • Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.

06

What researchers measure

Primary outcomes

  1. Percentage of Time When Participants Had Hemoglobin Levels Between 9 to 11 Gram Per Deciliter (g/dL)

    Time frame: Week 17 up to Week 24

Secondary outcomes

  1. Change From Baseline in Weekly Mean Study Medication Dose Over Final 8 Weeks of Study Treatment

    Time frame: Baseline (8 Weeks prior to randomization), Week 17 up to Week 24

07

Results

Posted Jun 13, 2018

Participant flow

Participant flow — Overall Study
MilestoneEpoetin HospiraEpogen
Started212206
Completed156158
Not completed5648
Withdrew: Adverse event1512
Withdrew: Withdrawal by subject71
Withdrew: Protocol violation2726
Withdrew: Physician decision12
Withdrew: Lost to follow-up67

Outcome measures

PrimaryPercentage of Time When Participants Had Hemoglobin Levels Between 9 to 11 Gram Per Deciliter (g/dL)
Time frame:
Week 17 up to Week 24
Reported as:
Number · Percentage of Weeks
Percentage of Time When Participants Had Hemoglobin Levels Between 9 to 11 Gram Per Deciliter (g/dL)
Percentage of WeeksEpoetin HospiraEpogen
Percentage of Time When Participants Had Hemoglobin Levels Between 9 to 11 Gram Per Deciliter (g/dL)61.9330 (57.5106 to 66.1659)63.3305 (58.7061 to 67.7217)
Statistical analysis
  • Epoetin Hospira vs Epogen · Difference in percentage: -1.3975 · 95% CI -7.6503 to 4.8553
SecondaryChange From Baseline in Weekly Mean Study Medication Dose Over Final 8 Weeks of Study Treatment
Time frame:
Baseline (8 Weeks prior to randomization), Week 17 up to Week 24
Reported as:
Least squares mean · Units per week
Change From Baseline in Weekly Mean Study Medication Dose Over Final 8 Weeks of Study Treatment
Units per weekEpoetin HospiraEpogen
Change From Baseline in Weekly Mean Study Medication Dose Over Final 8 Weeks of Study Treatment-1861.8 ± 563.50-799.8 ± 573.14
Statistical analysis
  • Epoetin Hospira vs Epogen · ANCOVA · p = 0.1874 · Ls mean difference: -1062.0 · 95% CI -2643.2 to 519.2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epoetin Hospira—66/212 (31.1%)10/212 (4.7%)
Epogen—64/206 (31.1%)21/206 (10.2%)
Most frequent serious events
Showing 10 of 134
Most frequent serious events
EventEpoetin HospiraEpogen
PneumoniaInfections and infestations7/2121/206
Cardiac arrestCardiac disorders2/2126/206
HyperkalaemiaMetabolism and nutrition disorders5/2121/206
Condition aggravatedGeneral disorders4/2123/206
Fluid overloadMetabolism and nutrition disorders4/2123/206
Cardiac failure congestiveCardiac disorders0/2123/206
Chest painGeneral disorders3/2121/206
SepsisInfections and infestations3/2121/206
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/821/102
AnaemiaBlood and lymphatic system disorders1/2122/206
Most frequent other events
Most frequent other events
EventEpoetin HospiraEpogen
NauseaGastrointestinal disorders3/21213/206
DyspnoeaRespiratory, thoracic and mediastinal disorders7/21211/206

Baseline characteristics

Full analysis set (FAS) included all participants who received at least 1 dose of study medication after randomization into the study.

Age, Continuous
Age, Continuous(Years)Epoetin HospiraEpogenTotal
Mean60.5 ± 13.9659.3 ± 14.2359.9 ± 14.09
Sex: Female, Male
Sex: Female, Male(Participants)Epoetin HospiraEpogenTotal
Female82102184
Male130104234
08

Study locations

45 sites
  • California Institute of Renal Research
    Chula Vista, California 91910, United States
  • California Institute of Renal Research at Fresenius Medical Care
    Poway, California 92064, United States
  • Fresenius Medical Care Rancho
    Rancho Bernardo, California 92127, United States
  • California Institute of Renal Research at Fresenius Medical Care Kearny Mesa
    San Diego, California 92111, United States
  • Fresenius Medical Care Paradise Valley
    San Diego, California 92139, United States
  • Fresenius Medical Care
    Tampa, Florida 33609, United States
  • Fresenius Medical Care
    Tampa, Florida 33610, United States
  • Genesis Clinical Research, LLC
    Tampa, Florida 33614, United States
  • Frenova Renal Research
    Boise, Idaho 83702, United States
  • Fresenius Medical Care North America - Liberty Dialysis
    Boise, Idaho 83702, United States
  • Frenova Renal Research
    Caldwell, Idaho 83605, United States
  • Fresenius Medical Care North America - Liberty Dialysis
    Caldwell, Idaho 83605, United States
  • Frenova Renal Research
    Meridian, Idaho 83642, United States
  • Fresenius Medical Care North America - Liberty Dialysis
    Meridian, Idaho 83642, United States
  • Frenova Renal Research
    Nampa, Idaho 83686, United States
  • Fresenius Medical Care North America - Liberty Dialysis
    Nampa, Idaho 83686, United States
  • Fresenius Medical Care-Kalamazoo East
    Kalamazoo, Michigan 49001, United States
  • Paragon Health PC DBA Nephrology Center
    Kalamazoo, Michigan 49007, United States
  • Fresenius Medical Care-Oshtemo
    Kalamazoo, Michigan 49009, United States
  • Fresenius Medical Care, Biloxi Dialysis Unit
    Biloxi, Mississippi 39530, United States
  • North Gulfport
    Gulfport, Mississippi 39501, United States
  • South Mississippi Kidney Center
    Gulfport, Mississippi 39503, United States
  • FMC Charlotte
    Charlotte, North Carolina 28204, United States
  • Metrolina Nephrology Associates, PA
    Charlotte, North Carolina 28204, United States
  • Briggs Avenue Dialysis Center
    Durham, North Carolina 27703, United States
  • Durham Nephrology Associates
    Durham, North Carolina 27704, United States
  • FMC Matthews
    Matthews, North Carolina 28105, United States
  • Fresenius Medical Care- Lansdale Dialysis
    Lansdale, Pennsylvania 19446, United States
  • Delaware Valley Nephrology and Hypertension Associates, PC
    Philadelphia, Pennsylvania 19118, United States
  • Fresenius Medical Care
    Warwick, Rhode Island 02886, United States
  • Fresenius Crossville Dialysis Unit
    Crossville, Tennessee 38555, United States
  • Fresenius Medical Care-Franklin
    Franklin, Tennessee 37067, United States
  • Knoxville Kidney Center, PLLC
    Knoxville, Tennessee 37923, United States
  • Fresenius Dialysis West
    Knoxville, Tennessee 37934, United States
  • Nephrology Associates, PC
    Nashville, Tennessee 37205, United States
  • Fresenius Medical Care - Austin North 4478
    Austin, Texas 78758, United States
  • Research Management Inc
    Austin, Texas 78758, United States
  • Mission Bend Dialysis (FMC#3971)
    Houston, Texas 77083, United States
  • Southwest Houston Research, Ltd.
    Houston, Texas 77099, United States
  • Gamma Medical Research Inc
    McAllen, Texas 78503, United States
  • Rosenberg Dialysis (FMC#1197)
    Rosenberg, Texas 77471, United States
  • Fresenius Medical Care Weslaco
    Weslaco, Texas 78596, United States
  • Fresenius Medical Care Carolina
    Carolina, 00983, Puerto Rico
  • Fresenius Medical Care
    Humacao, 00791, Puerto Rico
  • Fresenius Medical Care San Juan
    San Juan, 00917, Puerto Rico
09

References and documents

Publications

  • Thadhani R, Guilatco R, Hymes J, Maddux FW, Ahuja A. Switching from Epoetin Alfa (Epogen(R)) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis. Am J Nephrol. 2018;48(3):214-224. doi: 10.1159/000492621. Epub 2018 Sep 7. PubMed 30196301 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Jul 2016, 11 months.

Results were first posted in Jun 2018, 1 year 11 months after primary completion. A results delay was requested in Sep 2017.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 11 months is below that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2015
First posted
Jul 21, 2015
StartActual
Jul 13, 2015
Primary completionActual
Jul 2, 2016
CompletionActual
Jul 16, 2016
Results delay requested
Sep 7, 2017
Results first posted
Jun 13, 2018
Last update
Jun 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02504294
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 21, 2015
Start date
Jul 13, 2015
Primary completion
Jul 2, 2016
Completion
Jul 16, 2016
Results posted
Jun 13, 2018
Last update
Jun 13, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion